EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	1642	2,6-diisopropylphenol or propofol or propofolum	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/09/19 08:13
S2	888568	injection	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 10:20
S3	847	S1 and S2	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 10:33
S4	400	polyethylene adj glycol adj "660" adj hydroxystearate or solutol	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 10:27
S5	794	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj ether or glycofurol	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 10:28
S6	3	S3 and S4 and S5	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 10:28
S7	413	S1 and S2 @py<="2003"	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 10:34
S8	8840	bile adj salt	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2006/09/18 10:34
S9	56	S7 and S8	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2006/09/18 10:40
S10	4	S4 and S7	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2006/09/18 10:40
S11	1642	2,6-diisopropylphenol or propofol or propofolum	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/09/18 13:15

EAST Search History

S12	888568	injection	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/18 13:15
S13	794	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj ether or glycofurol	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:24
S14	34	S11 and S12 and S13	US-PGPUB; USPAT; EPO; DERWENT	AND	OFF	2006/09/18 13:16
S15	8	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj ether	US-PGPUB; USPAT; EPO; DERWENT	ADJ	ON	2006/09/18 13:25
S16	1278	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj glycofurol or tetraglycol or methoxy adj PEG	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:31
S17	18	S11 and S12 and S16	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:27
S18	1102762	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj glycofurol or tetraglycol or methoxy adj PEG or tetrahydrofurfuryl alcohol PEG ether	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:31
S19	1280	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj glycofurol or tetraglycol or methoxy adj PEG or tetrahydrofurfuryl adj alcohol adj PEG adj ether	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/18 13:31
S20	113	diprivan	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/19 08:17
S21	1665	diprivan or propofol or 2, 6-diisopropylphenol or propofolum	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/19 08:17
S22	1280	tetrahydrofurfuryl adj alcohol adj polyethyleneglycol adj glycofurol or tetraglycol or methoxy adj PEG or tetrahydrofurfuryl adj alcohol adj PEG adj ether	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/19 08:17

EAST Search History

S23	30	S21 and S22	US-PGPUB; USPAT; EPO; DERWENT	OR	ON	2006/09/19 08:18
S24	30	S21 and S22	US-PGPUB; USPAT; EPO; DERWENT	AND	ON	2006/09/19 08:18

```
FILE 'HOME' ENTERED AT 10:03:00 ON 19 SEP 2006

=> file caplus medline biosis embase
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 10:03:28 ON 19 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:03:28 ON 19 SEP 2006

FILE 'BIOSIS' ENTERED AT 10:03:28 ON 19 SEP 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:03:28 ON 19 SEP 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s 2,6-diisopropylphenol or propofol or propofolum
L1        39816 2,6-DIISOPROPYLPHENOL OR PROPOFOL OR PROPOFOLUM

=> s injection or microemulsion
L2      1617420 INJECTION OR MICROEMULSION

=> s l1 and l2
L3         4299 L1 AND L2

=> s polyethylene(w)glycol(w)660(w)hydroxystearate or solutol
L4          362 POLYETHYLENE(W) GLYCOL(W) 660(W) HYDROXYSTEARATE OR SOLUTOL

=> s tetrahydrofurfuryl(w)alcohol(w)polyethyleneglycol(w)ether or glycofurol or
tetraglycol or methoxy(w)PEG
L5          786 TETRAHYDROFURFURYL(W) ALCOHOL(W) POLYETHYLENEGLYCOL(W) ETHER OR
                GLYCOFUROL OR TETRAGLYCOL OR METHOXY(W) PEG

=> s l3 and l4 and l5
L6            2 L3 AND L4 AND L5

=> d ti au abs so py 1-2

L6   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Formulations containing propofol for anesthetic use
IN   Bell, Alan R.; Cochrane, Fenella; O'Connor, Geoffrey N.; Rowe, James S.
AB   A formulation for anesthetic use is described.  The formulation contains
     propofol, and may be used to induce and/or maintain anesthesia or
     sedation in a vertebrae.  The formulation addnl. contains a solvent or a
     combination of solvents and is suitable for mixing with commonly used
     infusion fluids prior to injection to a patient.  The
     formulation may be terminally sterilized using moist heat in order to
     assure sterility, and contains no lipid, thereby avoiding complications
     associated with administration over prolonged periods of time, or to patients
     with disorders of fat metabolism  For example, a solution was formulated
containing
     propofol 1, glycofurol 20, Solutol HS15 10,
     benzyl alc. 2, ethanol 2 % weight/volume, and water for injection to
     100 %.
SO   U.S. Pat. Appl. Publ., 12 pp.
     CODEN: USXXCO
PY   2005
     2005
     2004
     2004
```

```
L6   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Injectable 2,6-diisopropylphenol-containing
     anesthetic composition and methods
IN   Jee, Ung-kil
AB   An injectable anesthetic composition in a microemulsion phase is
     disclosed.  The composition contains 2,6-
     diisopropylphenol as the active ingredient, together with
     polyethylene glycol 660
     hydroxystearate, tetrahydrofurfuryl alc.
     polyethyleneglycol ether, and an aqueous medium.  Methods of
     making and using the injectable anesthetic composition are also disclosed.
SO   U.S. Pat. Appl. Publ., 9 pp.
     CODEN: USXXCO
PY   2004
     2004
     2004
     2004
     2005
     2005


=> s l3 and l5
L7            2 L3 AND L5

=> d ti au so py 1-2

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Formulations containing propofol for anesthetic use
IN   Bell, Alan R.; Cochrane, Fenella; O'Connor, Geoffrey N.; Rowe, James S.
SO   U.S. Pat. Appl. Publ., 12 pp.
     CODEN: USXXCO
PY   2005
     2005
     2004
     2004

L7   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Injectable 2,6-diisopropylphenol-containing
     anesthetic composition and methods
IN   Jee, Ung-kil
SO   U.S. Pat. Appl. Publ., 9 pp.
     CODEN: USXXCO
PY   2004
     2004
     2004
     2004
     2005
     2005


=> s cellulose
L8       466581 CELLULOSE

=> s l3 and l8
L9            3 L3 AND L8

=> s ti au abs py so 1-3
L10           0 TI AU ABS PY SO 1-3

=> d ti au abs py so 1-3
L10 HAS NO ANSWERS
'1-3 ' IS NOT A VALID SEARCH STATUS KEYWORD
Search status keywords:
```

```
NONE ---- Display only the number of postings.
STATUS -- Display statistics of the search.
ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ?:19
'L45' IS NOT A VALID SEARCH STATUS KEYWORD
Search status keywords:
NONE ---- Display only the number of postings.
STATUS -- Display statistics of the search.
ENTER SEARCH STATUS OPTION (NONE), STATUS, OR ?:none
L10             0 SEA TI AU ABS PY SO 1-3


=> d 19 ti au abs py so 1-3

L9   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Novel encochleation methods, cochleates and methods of use
IN   Mannino, Raphael J.; Gould-Fogerite, Susan; Krause-Elsmore, Sara L.;
     Delmarre, David; Lu, Ruying
AB   The invention generally relates to cochleate drug delivery vehicles.
     Disclose are novel methods for making cochleates and cochleate compns.
     that include introducing a cargo moiety to a liposome in the presence of a
     solvent.  Also disclosed are cochleates and cochleate compns. that include
     an aggregation inhibitor, and optionally, a cargo moiety.  Addnl., anhydrous
     cochleates that include a protonized cargo moiety, a divalent metal cation
     and a neg. charge lipid are disclosed.  Methods of using the cochleate
     compns. of the invention, including methods of administration, are also
     disclosed.
PY   2004
     2005
     2005
     2005
     2006
SO   PCT Int. Appl., 195 pp.
     CODEN: PIXXD2

L9   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Injectable 2,6-diisopropylphenol-containing
     anesthetic composition and methods
IN   Jee, Ung-kil
AB   An injectable anesthetic composition in a microemulsion phase is
     disclosed.  The composition contains 2,6-
     diisopropylphenol as the active ingredient, together with
     polyethylene glycol 660 hydroxystearate, tetrahydrofurfuryl alc.
     polyethyleneglycol ether, and an aqueous medium.  Methods of making and using
     the injectable anesthetic composition are also disclosed.
PY   2004
     2004
     2004
     2004
     2005
     2005
SO   U.S. Pat. Appl. Publ., 9 pp.
     CODEN: USXXCO

L9   ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Biodegradable injectable implants and related methods of manufacture and
     use
IN   Caseres, Crisofo Peralta; D'Lagarde, Daniel Leon
AB   This invention is directed to the field of medical implants, and more
     specifically to biodegradable injectable implants and their methods of
     manufacture and use.  The injectable implants disclosed herein comprise
     glycolic acid and bio-compatible/bio-absorbable polymeric particles containing
     a polymer of lactic acid.  The particles are small enough to be injected
     through a needle but large enough to avoid engulfment by macrophages.  The
     injectables of this invention may be in a pre-activated solid form or an
```

activated form (e.g., injectable suspension or emulsion). For example, a lyophilized composition was prepared containing glycolic acid 0.07 mg, poly(lactic acid) spheres 200.0 mg, hydroxypropyl Me cellulose 118.33 mg, D-mannitol 170.0 mg, pH stabilizer (phosphate buffer) 0.50 mg, and surfactant (Tween 80) 1.20 mg. The composition was activated extemporaneously with 5.5 mL water to obtain an injectable preparation

PY 2003
2003
2003
2003
2004
2004
2004
2005

SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2

=> s pH(w)regulator
L11 1080 PH(W) REGULATOR

=> s l3 and l11
L12 0 L3 AND L11

=> s acetate
L13 884590 ACETATE

=> s l3 and l13
L14 31 L3 AND L13

=> d ti au abs so py 1-5

L14 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI Lipid-based dispersions for drug delivery
IN Hu, Ning; Jensen, Gerard M.; Yang, Stephanie; Su-ming, Chiang
AB The invention provides lipid-based dispersion comprising comprising, phosphatidylcholine, an anionic phospholipid, up to 1% cholesterol by weight of total lipids, and a therapeutic agent, wherein the mean particle size measured by dynamic light scattering is <100 nm. The invention also provides pharmaceutical compns. comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion. Soy-phosphatidylcholine, DSPG, and propofol were dissolved in a 1:1 mixture of methanol and chloroform at a molar ratio of Soy-PC:DSPG of 1:0.4 and a weight ratio of (Soy-PC + DSPG):propofol of 10:1. Solvents were removed by evaporation and the films were then hydrated in 9% sucrose at desired drug concns. and sonicated to form liposomes.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
PY 2005
2006
2005
2005
2005

L14 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI Propofol formulation containing reduced oil and surfactants
IN Desai, Neil P.; Yang, Andrew; De, Tapas; Ci, Sherry Xiaopei; Soon-Shiong, Patrick
AB Sterile, stable pharmaceutical formulations of emulsions of neat propofol or propofol dissolved in a solvent and containing no preservative are provided that comprise optimal amts. of surfactants such as lecithin and solvent such as soybean oil, with a suitable pH range

to prevent significant growth of microorganisms for at least 24 h after extrinsic contamination. The lower amount of oil or absence (oil) in the formulation also allows chronic sedation over extended periods of time with a reduced chance of lipid overload in the blood. Formulations with the following general ranges of components for such propofol compns. were prepared as follows: propofol 0.5-5; human serum albumin 0.01-3; glycerol 2.25; water for injection qs to 100%.

SO U.S. Pat. Appl. Publ., 13 pp.
CODEN: USXXCO

PY 2004
2004
2005

L14 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI Propofol with cysteine
IN Tang, Hua; Chen, Hongming; Almarsson, Orn
AB The present invention relates to pharmaceutical compns. comprising 2,6-diisopropylphenol (propofol). Compns. of the present invention comprise aqueous and non-aqueous compns. of propofol and cysteine or a salt thereof. The propofol containing compns. are preferably sterile and are parenterally administered to any animal, including humans.

SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2

PY 2004
2004
2004
2004
2004
2005
2005
2006

L14 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI Substituted phenol compounds useful for anesthesia and sedation
IN Jenkins, Thomas E.; Ji, Yu-Hua; Wu, Huiwei; Bolton, Jennifer
AB Substituted phenol compds. and pharmaceutical compns. containing them, e.g., injections, which are useful for inducing or maintaining anesthesia or sedation in a mammal are provided. For example, 4-methoxycarbonyl-2,6-diisopropylphenol, prepared by the reaction of carbon tetrachloride, 2,6-diisopropylphenol and methanol, was used for the synthesis of 4-(2-methoxycarbonylethyl)-2,6-diisopropylphenol by its reaction with Et acetate.

SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2

PY 2003
2003
2003
2003
2004
2004
2005

L14 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
TI Novel pharmaceuticals comprising drug conjugates with polypeptide carriers
IN Picariello, Thomas
AB A pharmaceutical composition comprising a polypeptide and an active agent attached to said polypeptide is disclosed.

SO PCT Int. Appl., 2059 pp.
CODEN: PIXXD2

PY 2003
2003
2003

2003
2006
2004
2006

```
=> s diprivan or propofol or 2,6-diisopropylphenol or propofolum
L15         39943 DIPRIVAN OR PROPOFOL OR 2,6-DIISOPROPYLPHENOL OR PROPOFOLUM

=> d his

     (FILE 'HOME' ENTERED AT 10:03:00 ON 19 SEP 2006)

     FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE' ENTERED AT 10:03:28 ON 19 SEP 2006
L1          39816 S 2,6-DIISOPROPYLPHENOL OR PROPOFOL OR PROPOFOLUM
L2        1617420 S INJECTION OR MICROEMULSION
L3           4299 S L1 AND L2
L4            362 S POLYETHYLENE(W)GLYCOL(W)660(W)HYDROXYSTEARATE OR SOLUTOL
L5            786 S TETRAHYDROFURFURYL(W)ALCOHOL(W)POLYETHYLENEGLYCOL(W)ETHER OR
L6              2 S L3 AND L4 AND L5
L7              2 S L3 AND L5
L8         466581 S CELLULOSE
L9              3 S L3 AND L8
L10             0 S TI AU ABS PY SO 1-3
L11          1080 S PH(W)REGULATOR
L12             0 S L3 AND L11
L13        884590 S ACETATE
L14            31 S L3 AND L13
L15         39943 S DIPRIVAN OR PROPOFOL OR 2,6-DIISOPROPYLPHENOL OR PROPOFOLUM

=> s l15 and l2
L16          4308 L15 AND L2

=> s l16 and l4 and l5
L17             2 L16 AND L4 AND L5

=> s l16 and l11
L18             0 L16 AND L11

=> s l16 and l8
L19             3 L16 AND L8

=>
```